Loading data for PRPO — first visit, this takes a few seconds.
Precipio Inc. (PRPO)
NasdaqCM: PRPO
· Real-Time Price · USD
23.90
+0.40 (1.70%)
At close: Aug 19, 2026, 12:11 PM
Precipio Inc. (PRPO) Stock Price, Analysis & Data
1.70% (1D)
| Bid | 20.47 |
| Market Cap | 46.29M |
| Revenue (ttm) | 25.83M |
| Net Income (ttm) | -922K |
| Beta | 1.29 |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | n/a |
| Forward PE | 66.31 |
| P/B (ttm) | 3.26 |
| P/S (ttm) | 1.79 |
| Earnings Date | n/a |
| Ask | 28.38 |
| Volume | 49,383 |
| Avg. Volume (20D) | 71,819 |
| Open | 23.06 |
| Previous Close | 23.50 |
| Day's Range | 23.05 - 26.54 |
| 52-Week Range | 13.80 - 33.63 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRPO
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-ph...
Industry Diagnostics & Research
Sector Healthcare
IPO Date Jun 30, 2017
Employees 61
Stock Exchange NasdaqCM
Ticker Symbol PRPO
Website https://www.precipiodx.com
Financial Performance
In 2025, Precipio's revenue was 24.05M, an increase of 29.77% compared to the previous year's 18.53M. Earnings were -363K, a decrease of -91.54%.
Financial StatementsEarnings Surprise
Precipio has released their quarterly earnings on Nov 13, 2023:
Page 1 of 2